We are interested in deciphering the molecular mechanisms underlying aberrant signaling events that contribute to tumorigenesis mediated by protein modifications and protein-protein interactions. Understanding these events may lead to identification of novel drug targets and provide new treatment strategies to combat human cancer. To this end, we are interested in the potential of enzymes, and their inhibition, for generating traditional inhibitory chemical compounds or antibodies as potential therapeutic tools. Cell signaling networks determine cell fate and aberrant activation of oncogenic signaling is a key mechanism during cancer development; however, cell-signaling networks are complicated and dynamic with fluxes in both space and time. Thus, to understand how cancer-associated aberrant cell decisions are made requires addressing the following questions through a global view of cell signaling networks, including to identify the key molecular events that lead to malignant diseases but do not occur in healthy cells and to elucidate how can cancer-associated signaling modules be targeted for cancer treatment.